| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President and CEO
2 companies
Roger Pomerantz last filed a Form 4 in June 2025, as President and CEO at MCRB. The filings on record cover 2 companies. Roger Pomerantz's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 213,976 shares of MCRB. The MCRB filings lean toward selling, a net 824,466 shares.
Roger Pomerantz has 52 Form 4 filings on record from June 2015 to June 2025, across 3 companies: Director at Indaptus Therapeutics (INDP), 2021–2025; Director at Viracta Therapeutics (VIRX), 2021–2024; Director at Seres Therapeutics (MCRB), 2015–2019.
The 112 reported transactions were 49 open-market sales, 43 option exercises, 16 option or other derivative awards and 3 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 19 sales worth about $19.6M.
The largest open-market sale was 135,788 shares of MCRB at an average $27.20 on April 4, 2016, about $3.7M.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 7, 2018 | MCRB Seres Therapeutics, Inc. | President and CEO | Sell | 1,810 | $9.00 | $16,291.27 | -0.8% | |
| Sep 6, 2018 | MCRB Seres Therapeutics, Inc. | President and CEO | Sell | 12,518 | $9.10 | $113,949.53 | -5.5% | |
| Jul 11, 2018 | MCRB Seres Therapeutics, Inc. | President and CEO | Sale+OE | 1,010 | $9.01 | $9,098.99 | -0.4% | |
| Jul 10, 2018 | MCRB Seres Therapeutics, Inc. | President and CEO | Sale+OE | 32,336 | $9.12 | $295,065.31 | -12.4% | |
| Jun 29, 2018 | MCRB Seres Therapeutics, Inc. | President and CEO | Sale+OE | 26,056 | $9.15 | $238,290.73 | -10.2% | |
| Jun 27, 2018 | MCRB Seres Therapeutics, Inc. | President and CEO | Sale+OE | 64,967 | $9.16 | $595,045.43 | -22.2% | |
| Jun 22, 2018 | MCRB Seres Therapeutics, Inc. | President and CEO | Sell | 85,536 | $9.28 | $793,906.79 | -26.4% | |
| May 9, 2018 | MCRB Seres Therapeutics, Inc. | President and CEO | Sell | 233 | $9.00 | $2,097.00 | - | |
| Jul 27, 2016 | MCRB Seres Therapeutics, Inc. | President and CEO | Sale+OE | 20,000 | $35.00 | $700,000.00 | -9.8% | |
| Jul 6, 2016 | MCRB Seres Therapeutics, Inc. | President and CEO | Sale+OE | 88,211 | $29.45 | $2,597,473.97 | -32.4% |